FRX — Fennec Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00- CA$321.53m
- CA$320.83m
- $47.54m
- 26
- 28
- 50
- 26
Annual balance sheet for Fennec Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 30.3 | 21.1 | 23.8 | 13.3 | 26.6 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | — | — | 1.54 | 8.81 | 12.9 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 31.4 | 22.4 | 26.7 | 26.9 | 44.1 |
| Other Long Term Assets | |||||
| Total Assets | 31.4 | 22.4 | 26.9 | 26.9 | 44.9 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2.35 | 1.65 | 4.61 | 7.55 | 6.92 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 2.35 | 6.64 | 29.5 | 38.5 | 50.8 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 29.1 | 15.8 | -2.57 | -11.6 | -5.87 |
| Total Liabilities & Shareholders' Equity | 31.4 | 22.4 | 26.9 | 26.9 | 44.9 |
| Total Common Shares Outstanding |